Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Kaposi sarcoma: An unconventional cause of lower extremity lymphedema.

Dean SM, Kaffenberger BH, Lustberg ME.

Vasc Med. 2017 Dec;22(6):544. doi: 10.1177/1358863X17729031. Epub 2017 Sep 6. No abstract available.

PMID:
28875759
2.

Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.

Baden LR, Swaminathan S, Angarone M, Blouin G, Camins BC, Casper C, Cooper B, Dubberke ER, Engemann AM, Freifeld AG, Greene JN, Ito JI, Kaul DR, Lustberg ME, Montoya JG, Rolston K, Satyanarayana G, Segal B, Seo SK, Shoham S, Taplitz R, Topal J, Wilson JW, Hoffmann KG, Smith C.

J Natl Compr Canc Netw. 2016 Jul;14(7):882-913.

PMID:
27407129
3.

The Epstein-Barr Virus Lytic Protein BZLF1 as a Candidate Target Antigen for Vaccine Development.

Hartlage AS, Liu T, Patton JT, Garman SL, Zhang X, Kurt H, Lozanski G, Lustberg ME, Caligiuri MA, Baiocchi RA.

Cancer Immunol Res. 2015 Jul;3(7):787-94. doi: 10.1158/2326-6066.CIR-14-0242. Epub 2015 Mar 3.

4.

Human leukocyte antigen type and posttransplant lymphoproliferative disorder.

Lustberg ME, Pelletier RP, Porcu P, Martin SI, Quinion CD, Geyer SM, Caligiuri MA, Baiocchi RA.

Transplantation. 2015 Jun;99(6):1220-5. doi: 10.1097/TP.0000000000000487.

PMID:
25427163
5.

The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease.

Patton JT, Lustberg ME, Lozanski G, Garman SL, Towns WH, Drohan CM, Lehman A, Zhang X, Bolon B, Pan L, Kinghorn AD, Grever MR, Lucas DM, Baiocchi RA.

Oncotarget. 2015 Feb 20;6(5):2693-708.

6.

Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.

Yan F, Alinari L, Lustberg ME, Martin LK, Cordero-Nieves HM, Banasavadi-Siddegowda Y, Virk S, Barnholtz-Sloan J, Bell EH, Wojton J, Jacob NK, Chakravarti A, Nowicki MO, Wu X, Lapalombella R, Datta J, Yu B, Gordon K, Haseley A, Patton JT, Smith PL, Ryu J, Zhang X, Mo X, Marcucci G, Nuovo G, Kwon CH, Byrd JC, Chiocca EA, Li C, Sif S, Jacob S, Lawler S, Kaur B, Baiocchi RA.

Cancer Res. 2014 Mar 15;74(6):1752-65. doi: 10.1158/0008-5472.CAN-13-0884. Epub 2014 Jan 22.

7.

How much is a life worth? Food for thought.

Lustberg ME, Bauer KA.

Clin Infect Dis. 2013 Aug;57(4):627-8. doi: 10.1093/cid/cit311. Epub 2013 May 8. No abstract available.

8.

Beyond the bundle--journey of a tertiary care medical intensive care unit to zero central line-associated bloodstream infections.

Exline MC, Ali NA, Zikri N, Mangino JE, Torrence K, Vermillion B, St Clair J, Lustberg ME, Pancholi P, Sopirala MM.

Crit Care. 2013 Mar 4;17(2):R41. doi: 10.1186/cc12551.

9.

Sustained reduction of central line-associated bloodstream infections in an intensive care unit using a top-down and bottom-up approach.

Sopirala MM, Smyer J, Fawley L, Mangino JE, Lustberg ME, Lu J, Chucta S, Crouser ED.

Am J Infect Control. 2013 Feb;41(2):183-4. doi: 10.1016/j.ajic.2012.07.013. No abstract available.

PMID:
23369315
10.

Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.

Baiocchi RA, Alinari L, Lustberg ME, Lin TS, Porcu P, Li X, Johnston JS, Byrd JC, Blum KA.

Cancer. 2011 Jun 1;117(11):2442-51. doi: 10.1002/cncr.25792. Epub 2010 Dec 14.

11.

Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.

Alinari L, Yu B, Christian BA, Yan F, Shin J, Lapalombella R, Hertlein E, Lustberg ME, Quinion C, Zhang X, Lozanski G, Muthusamy N, Prætorius-Ibba M, O'Connor OA, Goldenberg DM, Byrd JC, Blum KA, Baiocchi RA.

Blood. 2011 Apr 28;117(17):4530-41. doi: 10.1182/blood-2010-08-303354. Epub 2011 Jan 12.

12.

A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.

Ramaswamy B, Phelps MA, Baiocchi R, Bekaii-Saab T, Ni W, Lai JP, Wolfson A, Lustberg ME, Wei L, Wilkins D, Campbell A, Arbogast D, Doyle A, Byrd JC, Grever MR, Shah MH.

Invest New Drugs. 2012 Apr;30(2):629-38. doi: 10.1007/s10637-010-9563-7. Epub 2010 Oct 12.

13.

Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma.

Lustberg MB, Bekaii-Saab T, Young D, Otterson G, Burak W, Abbas A, McCracken-Bussa B, Lustberg ME, Villalona-Calero MA.

J Thorac Oncol. 2010 May;5(5):713-8. doi: 10.1097/JTO.0b013e3181d7776d.

14.

Concerns about "Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study".

Lustberg ME, Schlesinger LS, Mangino JE.

Clin Infect Dis. 2009 Jul 15;49(2):313; author reply 314-5. doi: 10.1086/600056. No abstract available.

15.

Shock as a covariate in a study of treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Lustberg ME.

Clin Infect Dis. 2008 May 1;46(9):1483; author reply 1484-5. doi: 10.1086/587178. No abstract available.

PMID:
18419465
16.

Effect of physician training on fluoroscopy time during ERCP.

Uradomo LT, Lustberg ME, Darwin PE.

Dig Dis Sci. 2006 May;51(5):909-14. Epub 2006 May 23.

PMID:
16718536
17.

Febuxostat versus allopurinol for gout.

Lustberg ME.

N Engl J Med. 2006 Apr 6;354(14):1532-3; author reply 1532-3. No abstract available.

PMID:
16598054
18.

Effect modification by delta-aminolevulinic acid dehydratase, vitamin D receptor, and nitric oxide synthase gene polymorphisms on associations between patella lead and renal function in lead workers.

Weaver VM, Lee BK, Todd AC, Ahn KD, Shi W, Jaar BG, Kelsey KT, Lustberg ME, Silbergeld EK, Parsons PJ, Wen J, Schwartz BS.

Environ Res. 2006 Sep;102(1):61-9. Epub 2006 Feb 17.

PMID:
16487505
19.

Associations of uric acid with polymorphisms in the delta-aminolevulinic acid dehydratase, vitamin D receptor, and nitric oxide synthase genes in Korean lead workers.

Weaver VM, Schwartz BS, Jaar BG, Ahn KD, Todd AC, Lee SS, Kelsey KT, Silbergeld EK, Lustberg ME, Parsons PJ, Wen J, Lee BK.

Environ Health Perspect. 2005 Nov;113(11):1509-15.

20.

The G(894)-T(894) polymorphism in the gene for endothelial nitric oxide synthase and blood pressure in lead-exposed workers from Korea.

Lustberg ME, Schwartz BS, Lee BK, Todd AC, Silbergeld EK.

J Occup Environ Med. 2004 Jun;46(6):584-90.

PMID:
15213521
21.

Associations of patella lead with polymorphisms in the vitamin D receptor, delta-aminolevulinic acid dehydratase and endothelial nitric oxide synthase genes.

Theppeang K, Schwartz BS, Lee BK, Lustberg ME, Silbergeld EK, Kelsey KT, Parsons PJ, Todd AC.

J Occup Environ Med. 2004 Jun;46(6):528-37.

PMID:
15213514
22.

Associations of renal function with polymorphisms in the delta-aminolevulinic acid dehydratase, vitamin D receptor, and nitric oxide synthase genes in Korean lead workers.

Weaver VM, Schwartz BS, Ahn KD, Stewart WF, Kelsey KT, Todd AC, Wen J, Simon DJ, Lustberg ME, Parsons PJ, Silbergeld EK, Lee BK.

Environ Health Perspect. 2003 Oct;111(13):1613-9.

Supplemental Content

Loading ...
Support Center